Perifosine

Overview

Perifosine is a novel alkylphospholipid with antiproliferative properties attributed to protein kinase B inhibition.

Indication

Investigated for use/treatment in solid tumors, multiple myeloma, leukemia (unspecified), lung cancer, and brain cancer.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas	2014/09/12	NCT02238496	Phase 1	Completed	Andrew B Lassman, MD
A Food Effect and QTc Study of Perifosine in Patients With Advanced Malignancies	2010/10/20	NCT01224730	Phase 1	Completed	AEterna Zentaris
Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer	2010/04/01	NCT01097018	Phase 3	Completed	AEterna Zentaris
Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma	2010/01/18	NCT01051557	Phase 1	Completed	National Cancer Institute (NCI)
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors	2010/01/15	NCT01049841	Phase 1	Completed	Memorial Sloan Kettering Cancer Center
Study of Perifosine + Capecitabine for Colon Cancer Patients	2010/01/13	NCT01048580	Phase 1	Completed	AEterna Zentaris
Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients	2009/10/27	NCT01002248	Phase 3	Terminated	AEterna Zentaris
Perifosine in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma	2009/04/01	NCT00873457	Phase 2	Completed	Daphne Friedman
Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma	2009/02/19	NCT00847366	Not Applicable	Completed	AEterna Zentaris
Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors	2008/10/21	NCT00776867	Phase 1	Completed	Memorial Sloan Kettering Cancer Center

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access